Literature DB >> 35677508

Encephalopathy in Cirrhosis: Prevention and Management.

Amrish Sahney1, Manav Wadhawan1.   

Abstract

Hepatic encephalopathy (HE) is a major neuropsychiatric complication of cirrhosis. The clinical manifestations of HE ranges from mild confusion, disorientation to altered behaviour and coma in advanced stages. HE is an important cause of recurrent admissions in liver cirrhosis patients. HE is the most common cause of altered mentation in a patient of liver cirrhosis. Lactulose and rifaximin are approved treatment options for the treatment of HE. In patients who have localised neurological signs or are not improving with lactulose and rifaximin should be investigated for other causes of altered sensorium.
© 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALF, Acute Liver Failure; AMS, altered mental state; BCAA, Branched-chain Amino Acids; BRTO, balloon-occluded retrograde transvenous occlusion; CARTO, coil-assisted retrograde transvenous occlusion; FMT; HE, Hepatic encephalopathy; LOLA; OP, Ornithine phenylacetate; PARTO, plug-assisted retrograde transvenous occlusion; SIP, Sickness Impact Profile; cirrhosis; hepatic encephalopathy; lactulose; prevention; probiotics; rifaximin; treatment

Year:  2021        PMID: 35677508      PMCID: PMC9168742          DOI: 10.1016/j.jceh.2021.12.007

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  65 in total

Review 1.  Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver.

Authors:  Radha K Dhiman; Vivek A Saraswat; Barjesh K Sharma; Shiv K Sarin; Yogesh K Chawla; Roger Butterworth; Ajay Duseja; Rakesh Aggarwal; Deepak Amarapurkar; Praveen Sharma; Kaushal Madan; Samir Shah; Avnish K Seth; Rakesh K Gupta; Abraham Koshy; Ramesh R Rai; Jang B Dilawari; Sri Prakash Mishra; Subrat K Acharya
Journal:  J Gastroenterol Hepatol       Date:  2010-06       Impact factor: 4.029

2.  The relation between pathogenesis of liver cirrhosis, hepatic encephalopathy and serum cytokine levels: what is the role of tumor necrosis factor α?

Authors:  Vedat Goral; Yahya Atayan; Abdurahman Kaplan
Journal:  Hepatogastroenterology       Date:  2011 May-Jun

Review 3.  Management of hepatic encephalopathy in the hospital.

Authors:  Michael D Leise; John J Poterucha; Patrick S Kamath; W Ray Kim
Journal:  Mayo Clin Proc       Date:  2014-01-08       Impact factor: 7.616

4.  A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.

Authors:  Vibhu Vibhas Mittal; Barjesh Chander Sharma; Praveen Sharma; Shiv Kumar Sarin
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-08       Impact factor: 2.566

Review 5.  Why and when to measure ammonemia in cirrhosis?

Authors:  Maxime Mallet; Nicolas Weiss; Dominique Thabut; Marika Rudler
Journal:  Clin Res Hepatol Gastroenterol       Date:  2018-03-16       Impact factor: 2.947

6.  Normal protein diet for episodic hepatic encephalopathy: results of a randomized study.

Authors:  Juan Córdoba; Juan López-Hellín; Mercé Planas; Pilar Sabín; Francesc Sanpedro; Francisco Castro; Rafael Esteban; Jaume Guardia
Journal:  J Hepatol       Date:  2004-07       Impact factor: 25.083

7.  Altered mental status in cirrhosis: etiologies and outcomes.

Authors:  Robert S Rahimi; Alan C Elliott; Don C Rockey
Journal:  J Investig Med       Date:  2013-04       Impact factor: 2.895

8.  Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy.

Authors:  Wim Laleman; Macarena Simon-Talero; Geert Maleux; Mercedes Perez; Koen Ameloot; German Soriano; Jordi Villalba; Juan-Carlos Garcia-Pagan; Marta Barrufet; Rajiv Jalan; Jocelyn Brookes; Evangelos Thalassinos; Andrew K Burroughs; Juan Cordoba; Frederik Nevens
Journal:  Hepatology       Date:  2013-05-01       Impact factor: 17.425

Review 9.  Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials.

Authors:  Lise L Gluud; Gitte Dam; Mette Borre; Iñigo Les; Juan Cordoba; Giulio Marchesini; Niels K Aagaard; Niels Risum; Hendrik Vilstrup
Journal:  J Nutr       Date:  2013-06-05       Impact factor: 4.798

10.  Cognitive Impairment After Resolution of Hepatic Encephalopathy: A Systematic Review and Meta-Analysis.

Authors:  Óscar López-Franco; Jean-Pascal Morin; Albertina Cortés-Sol; Tania Molina-Jiménez; Diana I Del Moral; Mónica Flores-Muñoz; Gabriel Roldán-Roldán; Claudia Juárez-Portilla; Rossana C Zepeda
Journal:  Front Neurosci       Date:  2021-03-10       Impact factor: 4.677

View more
  1 in total

Review 1.  Management of Portal Hypertension.

Authors:  Anand V Kulkarni; Atoosa Rabiee; Arpan Mohanty
Journal:  J Clin Exp Hepatol       Date:  2022-03-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.